Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Analysts See Rise of Zafgen Inc (ZFGN) Earnings Per Share

Zafgen, Inc. is a biopharmaceutical company. The company has a market cap of $171.95 million. The Firm is engaged in improving the health and well-being of patients affected by Obesity and complex metabolic disorders. It currently has negative Earnings. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

The post Analysts See Rise of Zafgen Inc (ZFGN) Earnings Per Share appeared first on Octafinance.



This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Analysts See Rise of Zafgen Inc (ZFGN) Earnings Per Share

×

Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription

×